Mark W. Frohlich, M.D.
Dr. Frohlich serves as Dendreon’s executive vice president of research and development and chief medical officer. Dr. Frohlich previously served as vice president of clinical affairs, and prior to that, served as senior medical director. Prior to joining Dendreon, Dr. Frohlich was vice president and medical director at Xcyte Therapies, a biotechnology company. Prior to that, he was an assistant professor in the division of hematology/oncology at the University of California, San Francisco, where he specialized in urologic oncology and was active in laboratory, translational and clinical research. Dr. Frohlich did his postdoctoral training in oncology at the University of California, San Francisco. He received his B.S. from Yale University in electrical engineering and economics and his M.D. from Harvard Medical School.